Zoetis Inc. (NYSE:ZTS) Shares Acquired by Huntington National Bank

Huntington National Bank increased its position in Zoetis Inc. (NYSE:ZTS) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 249,247 shares of the company’s stock after acquiring an additional 13,757 shares during the period. Huntington National Bank owned approximately 0.06% of Zoetis worth $48,698,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Avantax Advisory Services Inc. lifted its stake in Zoetis by 6.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 10,223 shares of the company’s stock valued at $1,730,000 after buying an additional 596 shares in the last quarter. HBK Sorce Advisory LLC lifted its stake in Zoetis by 1.8% in the 1st quarter. HBK Sorce Advisory LLC now owns 6,030 shares of the company’s stock valued at $1,020,000 after buying an additional 104 shares in the last quarter. Orion Portfolio Solutions LLC lifted its stake in Zoetis by 10.8% in the 1st quarter. Orion Portfolio Solutions LLC now owns 66,099 shares of the company’s stock valued at $11,185,000 after buying an additional 6,441 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in Zoetis by 16.0% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 4,643 shares of the company’s stock valued at $786,000 after buying an additional 641 shares in the last quarter. Finally, Great Lakes Retirement Inc. lifted its stake in Zoetis by 4.2% in the 1st quarter. Great Lakes Retirement Inc. now owns 6,794 shares of the company’s stock valued at $1,150,000 after buying an additional 271 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $177.28 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company’s 50-day simple moving average is $187.81 and its 200-day simple moving average is $180.04. The stock has a market capitalization of $79.98 billion, a price-to-earnings ratio of 33.32, a PEG ratio of 2.67 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the company posted $1.36 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. Zoetis’s dividend payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler increased their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.